 Cytochrome P-450 CYP2C19
"Cytochrome P-450 CYP2C19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.
| Descriptor ID |
D065731
|
| MeSH Number(s) |
D08.244.453.491.500.700 D08.811.682.690.708.170.450.500.700 D12.776.422.220.453.491.500.700
|
| Concept/Terms |
Cytochrome P-450 CYP2C19- Cytochrome P-450 CYP2C19
- CYP2C19, Cytochrome P-450
- Cytochrome P 450 CYP2C19
- P-450 CYP2C19, Cytochrome
- CYPIIC19
- S-Mephenytoin 4'-Hydroxylase
- 4'-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4' Hydroxylase
- CYP2C19
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C19".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C19".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C19" by people in this website by year, and whether "Cytochrome P-450 CYP2C19" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2024 | 2 | 0 | 2 | | 2025 | 2 | 1 | 3 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C19" by people in Profiles.
-
Shen C, Adams MJ, Davyson E, Iveson MH, Cox SR, Harris SE, McIntosh AM, Shen X. The non-linear and linear effects of CYP2C19 metaboliser status on DNA methylation: a methylome-wide association study. Clin Epigenetics. 2026 Apr 22; 18(1).
-
Henthorn TK, Kharasch ED. Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model. Clin Pharmacol Ther. 2026 03; 119(3):739-750.
-
Chanfreau-Coffinier C, Friede KA, Plomondon ME, Lee KM, Lu Z, Dinatale T, DuVall SL, Vassy JL, Waldo SW, Cleator JH, Maddox TM, Rader DJ, Assimes TL, Damrauer SM, Tsao PS, Chang KM, Voora D, Lynch JA, Giri J, Tuteja S. CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program. Clin Pharmacol Ther. 2025 Oct; 118(4):876-884.
-
Kamp M, Lo CWH, Kokkinidis G, Chauhan M, Gillett AC, McIntosh AM, Pain O, Lewis CM. Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank. Psychol Med. 2025 Mar 12; 55:e80.
-
Li D, Pain O, Fabbri C, Wong WLE, Lo CWH, Ripke S, Cattaneo A, Souery D, Dernovsek MZ, Henigsberg N, Hauser J, Lewis G, Mors O, Perroud N, Rietschel M, Uher R, Maier W, Baune BT, Biernacka JM, Bondolfi G, Domschke K, Kato M, Liu YL, Serretti A, Tsai SJ, Weinshilboum R, McIntosh AM, Lewis CM. Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis. Transl Psychiatry. 2024 07 19; 14(1):296.
-
Aquilante CL, Trinkley KE, Lee YM, Crooks KR, Hearst EC, Heckman SM, Hess KW, Kudron EL, Martin JL, Swartz CT, Kao DP. Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. Am J Health Syst Pharm. 2024 06 11; 81(12):555-562.
-
Brown T, Gonzales N. Optimizing Choice of Dual Antiplatelet Therapy in CYP2C19 Loss-of-Function Carriers. Neurology. 2023 01 31; 100(5):223-224.
-
Anderson HD, Thant TM, Kao DP, Crooks KR, Mendola ND, Aquilante CL. Pharmacogenetic testing among patients with depression in a US managed care population. Clin Transl Sci. 2022 07; 15(7):1644-1653.
-
Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Bishop JR. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci. 2022 02; 15(2):371-383.
-
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|